Allogene Therapeutics
Yanqi C. currently serves as Associate Director and previously held the position of Senior Principal Scientist at Allogene Therapeutics. Prior experience includes roles as Senior Scientist in Discovery Biologics at Merck and Scientist II in Protein Science at NGM Biopharmaceuticals. Yanqi C. also completed postdoctoral training at both the New York Structural Biology Center and Emory University.
This person is not in the org chart
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.